Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 450

Results For "AI"

9540 News Found

FDA approves Lenire device by Neuromod for tinnitus treatment option for US veterans
Medical Device | June 19, 2024

FDA approves Lenire device by Neuromod for tinnitus treatment option for US veterans

Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government


Pfizer reports positive results from Echelon-3 study
Clinical Trials | June 17, 2024

Pfizer reports positive results from Echelon-3 study

Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone


Indian medical device industry to touch US$ 50 billion by 2030
Healthcare | June 17, 2024

Indian medical device industry to touch US$ 50 billion by 2030

India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%


Health Minister J P Nadda takes review meeting of Department of Pharmaceuticals
Policy | June 17, 2024

Health Minister J P Nadda takes review meeting of Department of Pharmaceuticals

Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department


USFDA approves next-gen TKI Augtyro for treatment of solid tumors
Drug Approval | June 17, 2024

USFDA approves next-gen TKI Augtyro for treatment of solid tumors

Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors


Lupin appoints Abdelaziz Toumi as CEO of its API CDMO subsidiary
People | June 17, 2024

Lupin appoints Abdelaziz Toumi as CEO of its API CDMO subsidiary

Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,


Imfinzi approved in the US for endometrial cancer
Drug Approval | June 17, 2024

Imfinzi approved in the US for endometrial cancer

Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy


Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27%
Clinical Trials | June 17, 2024

Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27%

First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting


Sun Pharma and Moebius Medical present Phase 2b study on MM-II
Clinical Trials | June 15, 2024

Sun Pharma and Moebius Medical present Phase 2b study on MM-II

There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis